košarica
0.00 €Tirzepatide
10 mg98.5% purityLot #TIRZEP-2026-001
Šifra odabrane dimenzije: PEP-TIRZ-10MG
Tirzepatide is an innovative dual incretin receptor agonist that simultaneously targets both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. Unlike traditional GLP-1 agonists that focus on a single pathway, Tirzepatide engages two complementary metabolic signaling systems at the same time, creating a synergistic effect that surpasses the outcomes typically achieved through single-receptor activation.
Activation of the GIP receptor supports enhanced lipid utilization and promotes fat oxidation within adipose tissue, while stimulation of the GLP-1 receptor helps regulate appetite, improve satiety, and optimize blood glucose control. One of the most significant studies evaluating Tirzepatide, the SURMOUNT-1 Phase III trial published in the New England Journal of Medicine, reported body weight reductions reaching 22.5% over a 72-week period, establishing Tirzepatide as one of the most effective metabolic peptides investigated to date. Additional clinical findings have demonstrated favorable effects on liver fat accumulation, blood pressure regulation, triglyceride levels, and broader metabolic health markers.
€267.18s PDV-om
✅ na zalihi (40)
Količinski popusti
| Količina | Cijena / kom | Ušteda |
|---|---|---|
| 1 vial | 267.18 € | — |
| 3 vials (−7%) | 248.88 € | −7% |
| 5 vials (−12%) | 235.46 € | −12% |
Ocene in mnenja
Prijavite se in ocenite izdelek po prejetem naročilu. prijava
Certifikat analize
Lab verificirano✓Pogledajte COA prije kupnje — transparentnost zajamčena
Istraživački profil
Tirzepatide — znanstveni profil
Sadržaj je namijenjen obrazovnim i istraživačkim svrhama. Research Use Only.
- Tirzepatide is an innovative dual incretin receptor agonist that simultaneously targets both GIP (Glucose-dependent Insulinotropic Polypeptide) and GLP-1 (Glucagon-Like Peptide-1) receptors. Unlike traditional GLP-1 agonists that focus on a single pathway, Tirzepatide engages two complementary metabolic signaling systems at the same time, creating a synergistic effect that surpasses the outcomes typically achieved through single-receptor activation.
- Activation of the GIP receptor supports enhanced lipid utilization and promotes fat oxidation within adipose tissue, while stimulation of the GLP-1 receptor helps regulate appetite, improve satiety, and optimize blood glucose control. One of the most significant studies evaluating Tirzepatide, the SURMOUNT-1 Phase III trial published in the New England Journal of Medicine, reported body weight reductions reaching 22.5% over a 72-week period, establishing Tirzepatide as one of the most effective metabolic peptides investigated to date. Additional clinical findings have demonstrated favorable effects on liver fat accumulation, blood pressure regulation, triglyceride levels, and broader metabolic health markers.
%22%20stroke-width%3D%223%22%2F%3E%3Ccircle%20cx%3D%2278%22%20cy%3D%2292%22%20r%3D%228%22%20fill%3D%22var(--pep-gray-light)%22%2F%3E%3Cpath%20d%3D%22M55%20125%20L95%2095%20L125%20115%20L145%2090%22%20fill%3D%22none%22%20stroke%3D%22var(--pep-gray-light)%22%20stroke-width%3D%223%22%20stroke-linecap%3D%22round%22%20stroke-linejoin%3D%22round%22%2F%3E%3C%2Fsvg%3E)